- Neuralstem (CUR +18.6%) hits the enrollment target of 220 subjects ahead of schedule in its Phase 2 clinical trial evaluating NSI-189 for the treatment of major depressive disorder (MDD). Top-line data should be available in Q3.
- The company says small molecule NSI-189 stimulates neurogenesis, synaptogenesis and increases hippocampal volume, all of which play a role in reversing depression, enhancing cognition and promoting the growth of new nerve tissue.
- Previously: First patient enrolled in Neuralstem's mid-stage study of NSI-189 in MDD, top-line data expected in H2 2017 (May 12, 2016)